These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22610787)

  • 41. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease.
    Tiev KP; Rivière S; Hua-Huy T; Cabane J; Dinh-Xuan AT
    Nitric Oxide; 2014 Aug; 40():17-21. PubMed ID: 24831352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
    Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K; Pope JE
    Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
    Mendoza FA; Allawh T; Jimenez SA
    Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
    Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.
    Schnabel A; Reuter M; Gross WL
    Arthritis Rheum; 1998 Jul; 41(7):1215-20. PubMed ID: 9663478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
    Kundu S; Paul S; Hariprasath K; Agarwal R; Ghosh S; Biswas D
    Indian J Chest Dis Allied Sci; 2016; 58(1):7-10. PubMed ID: 28368564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis.
    Takahashi H; Kuroki Y; Tanaka H; Saito T; Kurokawa K; Chiba H; Sagawa A; Nagae H; Abe S
    Am J Respir Crit Care Med; 2000 Jul; 162(1):258-63. PubMed ID: 10903251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis.
    Furuya Y; Okazaki Y; Kaji K; Sato S; Takehara K; Kuwana M
    Rheumatology (Oxford); 2010 Dec; 49(12):2375-80. PubMed ID: 20724431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous Cyclophosphamide for Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis Refractory to Endoscopic Treatment: A Case Report and Review of the Pertinent Literature.
    Matsumoto Y; Hayashi H; Tahara K; Yasuda T; Tsubouchi S; Yamamoto Y; Mizuuchi T; Mori H; Sawada T
    Intern Med; 2019 Jan; 58(1):135-139. PubMed ID: 30101944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
    Iudici M; Moroncini G; Cipriani P; Giacomelli R; Gabrielli A; Valentini G
    Autoimmun Rev; 2015 Jul; 14(7):575-8. PubMed ID: 25709096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease.
    Kwon HM; Kang EH; Park JK; Go DJ; Lee EY; Song YW; Lee HJ; Lee EB
    Rheumatology (Oxford); 2015 Oct; 54(10):1792-6. PubMed ID: 25972389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The effect of cyclophosphamide on cytokines in patients with primary Sjögren's syndrome-associated interstitial lung disease].
    Mo HY; Wang LF; Xu J; Shi YH; Yang M; Zhou RH
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jul; 34(7):495-9. PubMed ID: 22041773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis--association with pulmonary involvement.
    Dziankowska-Bartkowiak B; Waszczykowska E; Dziankowska-Zaboroszczyk E; de Graft-Johnson JE; Zalewska A; Łuczyńska M; Nowak D
    Clin Exp Rheumatol; 2006; 24(5):508-13. PubMed ID: 17181918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased sputum caveolin-1 is associated with systemic sclerosis related lung disease.
    Yilmaz N; Olgun S; Ahiskali R; Karakurt S; Yavuz S
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):55-61. PubMed ID: 24751454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases.
    Okada M; Suzuki K; Matsumoto M; Nakashima M; Nakanishi T; Takada K; Horikoshi H; Matsubara O; Ohsuzu F
    Mod Rheumatol; 2007; 17(2):131-6. PubMed ID: 17437168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.